REG - Hikma Pharmaceutical - Hikma appoints new President of Generics business

Hikma PharmaceuticalsAnnouncement

15/04/2024 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO6841Ka&default-theme=true

RNS Number : 6841K  Hikma Pharmaceuticals Plc  15 April 2024

Hikma appoints Dr. Hafrun Fridriksdottir as President of Generics business

London, 15 April 2024 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
announces that Dr. Hafrun Fridriksdottir has been appointed President of its
Generics business, effective today. Hafrun will report to Riad Mishlawi,
Hikma's Chief Executive Officer, and joins the senior management team as a
member of Hikma's Executive Committee.  She will be based in the company's
Berkeley Heights, New Jersey offices. Hafrun succeeds Brian Hoffmann, who will
leave Hikma effective May 1st.

Hafrun brings more than 25 years of pharmaceutical industry experience to her
new role.  During her career, Hafrun has held senior executive and research
and development positions at leading global pharmaceutical companies including
Alvotech, Teva Pharmaceuticals, Allergan and Actavis, and most recently has
served in advisory and board roles for several biotech and mid-sized pharma
companies.

"I am pleased to appoint Hafrun to this vital role," said Riad.  "Hafrun's
vast experience in leading high performing research and development teams
brings new capabilities needed for driving Hikma's Generics business in its
next phase of growth. She will be especially helpful in further expanding
Hikma's product portfolio and its position as a market-leading domestic US
manufacturer and supplier of generic medicines.  On behalf of Hikma's Board
of Directors and our executive management team, I want to thank Brian for his
many contributions to Hikma during his 15 years with the company."

Hafrun added: "This is a very exciting opportunity for me to lead a highly
talented team, who have been growing and developing this business over many
years. I am confident that together we will strengthen our R&D pipeline,
leverage our strong manufacturing capabilities and establish new business
opportunities that will further build our position as one of the top providers
of generic medicines in the US."

- ENDS -

Hikma (Investors):

 Susan Ringdal                                +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                             +44 (0)20 3892 4389/ +44 (0)7795 896738

 Director, Investor Relations
 Layan Kalisse                                +44 (0)20 7399 2788/ +44 (0)7970 709912

 Senior Associate, Investor Relations

 

Press:
 

Teneo - Douglas
Campbell                                  +44
(0)7703 330269/ +44 (0)7715 375443

Hikma - Steve
Weiss
+1-732-788-8279

 

About Hikma:

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our over 9,000 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Csweiss%40Hikma.com%7C4a35048c8c764c63c86308d70efbac9e%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C1%7C636994346427346162&sdata=lHZaoOb0u30Y6re6yfLW1Ar4vvBS%2FnjEUNdB00TBaTI%3D&reserved=0)

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAIAMATMTIBBBI